Unknown

Dataset Information

0

The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.


ABSTRACT: In response to DNA damage, the cell cycle checkpoint kinase 2 (CHEK2) may phosphorylate p53, Cdc25A and Cdc25C, and regulate BRCA1 function, leading to cell cycle arrest and DNA repair. The truncating germline mutation CHEK2(*)1100delC abrogates kinase activity and confers low-penetrance susceptibility to breast cancer. We found CHEK2(*)1100delC in 0.5% of 190 oesophageal squamous cell carcinomas and in 1.5% of 196 oesophageal adenocarcinomas. In addition, we observed the mutation in 3.0% of 99 Barrett's metaplasias and 1.5% of 66 dysplastic Barrett's epithelia, both known precursor lesions of oesophageal adenocarcinoma. Since CHEK2(*)1100delC mutation frequencies did not significantly differ among oesophageal squamous cell carcinomas, adenocarcinomas and (dysplastic) Barrett's epithelia, as compared to healthy individuals, we conclude that the CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.

SUBMITTER: Koppert LB 

PROVIDER: S-EPMC2410163 | biostudies-other | 2004 Feb

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC5842438 | biostudies-literature
| S-EPMC10687070 | biostudies-literature
| S-EPMC2747557 | biostudies-literature
| S-EPMC1891494 | biostudies-other
| S-EPMC7953736 | biostudies-literature
| S-EPMC7156420 | biostudies-literature
| S-EPMC4032983 | biostudies-literature
2022-11-01 | GSE162508 | GEO
| S-EPMC6744682 | biostudies-literature
| S-EPMC2361569 | biostudies-literature